Alvotech (ALVO) Competitors

Alvotech has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market.

Alvotech has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Alvotech currently has a consensus price target of $7.60, suggesting a potential upside of 131.71%. Structure Therapeutics has a consensus price target of $110.55, suggesting a potential upside of 107.17%. Given Alvotech's higher probable upside, research analysts plainly believe Alvotech is more favorable than Structure Therapeutics.

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Structure Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Structure Therapeutics' return on equity.

In the previous week, Structure Therapeutics had 1 more articles in the media than Alvotech. MarketBeat recorded 2 mentions for Structure Therapeutics and 1 mentions for Alvotech. Structure Therapeutics' average media sentiment score of 1.87 beat Alvotech's score of 0.79 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Alvotech has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market.

Telix Pharmaceuticals has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Telix Pharmaceuticals' return on equity of 0.00% beat Alvotech's return on equity.

Alvotech currently has a consensus price target of $7.60, suggesting a potential upside of 131.71%. Telix Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 88.51%. Given Alvotech's higher probable upside, research analysts plainly believe Alvotech is more favorable than Telix Pharmaceuticals.

In the previous week, Telix Pharmaceuticals had 7 more articles in the media than Alvotech. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.79 beat Telix Pharmaceuticals' score of 0.47 indicating that Alvotech is being referred to more favorably in the media.

Alvotech has higher earnings, but lower revenue than Telix Pharmaceuticals.

Alvotech has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Dyne Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Dyne Therapeutics' return on equity.

In the previous week, Dyne Therapeutics had 9 more articles in the media than Alvotech. MarketBeat recorded 10 mentions for Dyne Therapeutics and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.79 beat Dyne Therapeutics' score of 0.47 indicating that Alvotech is being referred to more favorably in the media.

Alvotech has higher revenue and earnings than Dyne Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

96.7% of Dyne Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alvotech currently has a consensus price target of $7.60, suggesting a potential upside of 131.71%. Dyne Therapeutics has a consensus price target of $34.17, suggesting a potential upside of 45.89%. Given Alvotech's higher possible upside, equities analysts clearly believe Alvotech is more favorable than Dyne Therapeutics.

Beam Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Beam Therapeutics presently has a consensus price target of $46.85, indicating a potential upside of 43.35%. Alvotech has a consensus price target of $7.60, indicating a potential upside of 131.71%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than Beam Therapeutics.

Alvotech has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

99.7% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 13 more articles in the media than Alvotech. MarketBeat recorded 14 mentions for Beam Therapeutics and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.79 beat Beam Therapeutics' score of 0.50 indicating that Alvotech is being referred to more favorably in the news media.

Alvotech has a net margin of -14.36% compared to Beam Therapeutics' net margin of -39.66%. Alvotech's return on equity of -11.92% beat Beam Therapeutics' return on equity.